Mike Rea
CEO, IDEA Pharma
Mike is a stalwart of the Power List, first appearing in the 2017 iteration, and then in consecutive years since. IDEA Pharma’s annual Pharmaceutical Innovation & Invention Indices records, tracks, and charts the ingenuity progress inherent in the industry to determine how companies establish value through their pipelines. Mike’s 2024 index accurately predicted a huge power shift in favor of Novo Nordisk and its GLP-1 pipeline. He is also a Senior Fellow, FasterCures, at Milken Institute; an advisor at BioEthics International and OneHealth/FidoCure; and the owner and Chief Musical Officer of indie record label Medical Records. He can be found on the stage at many events throughout the year, or otherwise reading a book.
“The exciting thing about the inefficiency of our industry is just how many companies are working at the one percent gains, which could collectively lead to large leaps. One of those leaps could be a company dedicated to changing everything – taking all of those learnings into one company – that means we can launch drugs more effectively, and more cost effectively. Imagine if, like most other industries, we expected the price of drugs to come down over time, instead of going up inexorably.”
